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Abstract: Amyloid aggregation is a hallmark of several degenerative diseases affecting the 
brain or peripheral tissues, whose intermediates (oligomers, protofibrils) and final mature 
fibrils display different toxicity. Consequently, compounds counteracting amyloid 
aggregation have been investigated for their ability (i) to stabilize toxic amyloid precursors; 
(ii) to prevent the growth of toxic oligomers or speed that of fibrils; (iii) to inhibit fibril 
growth and deposition; (iv) to disassemble preformed fibrils; and (v) to favor amyloid 
clearance. Natural phenols, a wide panel of plant molecules, are one of the most actively 
investigated categories of potential amyloid inhibitors. They are considered responsible for 
the beneficial effects of several traditional diets being present in green tea, extra virgin 
olive oil, red wine, spices, berries and aromatic herbs. Accordingly, it has been proposed 
that some natural phenols could be exploited to prevent and to treat amyloid diseases, and 
recent studies have provided significant information on their ability to inhibit peptide/protein 
aggregation in various ways and to stimulate cell defenses, leading to identify shared or 
specific mechanisms. In the first part of this review, we will overview the significance and 
mechanisms of amyloid aggregation and aggregate toxicity; then, we will summarize the 
recent achievements on protection against amyloid diseases by many natural phenols. 
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1. Introduction 
The cellular genome encodes not only the amino acid sequences and the specific three-dimensional 
structures of proteins associated with their biological functions, but also the way these structures are 
attained through protein folding, a self-organization process, whose information is completely 
contained within the primary structure of the polypeptide chain. In the last 10–15 years, a combination 
of theoretical and experimental studies has unraveled many key features of protein folding, the 
mechanisms responsible for its control in living systems and the key role of these mechanisms in 
maintaining cell wellness and tissue functionality [1]. Such information has raised a number of 
important new issues. For example, it has become clear that protein folding and unfolding are 
intrinsically associated with several cellular processes, including molecular trafficking within or 
between cells and tissues, crossing of cell membranes, cell cycle regulation and immune responses. 
Such observations have led to conclude that any failure of a specific protein/peptide to fold/unfold 
correctly or to remain properly folded (misfolding) is at the basis of different types of biological 
malfunctions, resulting in various types of diseases most often characterized by the presence of 
deposits of ordered protein aggregates in the affected tissues [2].  
It is well established that ―misfolded‖ proteins, i.e., proteins partially or completely devoid of the 
conformation associated with optimal stability and biological function, are more or less inactive, thus 
explaining the ―loss-of-function‖ features of the associated pathologies; however, this process can also 
lead misfolded polypeptide chains to gain a ―toxic‖ conformation, which enables them to aggregate 
into ordered polymeric assemblies and/or to interact inappropriately with other cellular components, 
impairing cell viability and function and, eventually, resulting in cell death [3,4]. Therefore, the 
molecular basis of these ―protein misfolding diseases‖, or ―conformational diseases‖, may ultimately 
be traced back to the presence, in a living system, of protein or peptide molecules with incorrect 
structures, different from those found in normally functioning organisms [5–7]. The most important 
subset of protein misfolding diseases includes conditions whose molecular basis can be traced back to 
a toxic ―gain-of-function‖, whereby specific peptides/proteins in their unstable, misfolded state  
self-organize into insoluble, cytotoxic, ordered and stable fibrillar polymeric assemblies with shared 
conformational features (amyloid aggregates) [8].  
Indeed, protein misfolding and its frequent outcome, aggregation, is one of the most exciting new 
frontiers in protein science, cell biology and molecular medicine. Presently, it is thought that protein 
folding and aggregation are determined by similar physicochemical properties and, hence, are 
competing processes [9–11]; accordingly, a better knowledge of the molecular basis of protein 
misfolding and aggregation may help to elucidate the structural determinants and the physicochemical 
features of protein folding and vice versa. However, it is also expected to shed light on the molecular 
and biochemical basis of a number of pathological conditions, some of which with severe medical and 
social impact, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), type 2 diabetes, cystic 
fibrosis, some forms of emphysema, familial hypercholesterolemia and others, for which effective 
therapy is presently lacking [3,4]. Such information will provide clues to develop possible therapeutic 
strategies suitable to hinder growth and deposition or to favor removal of amyloid aggregates or their 
precursors, as well as to foster the cell defenses against amyloid toxicity. 
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In amyloid diseases, the failure of specific peptides or proteins to fold or to remain correctly folded 
triggers aggregate nucleation, the first step of a process eventually giving rise to fibrillar amyloid 
deposits in tissue. The involved polypeptides may include full length proteins, biological peptides or 
peptide fragments arising from proteolytic processing of larger precursors [3,4]. Usually, the 
aggregated peptides/proteins display wild-type (wt) sequences, as it happens in the sporadic forms of 
the diseases; however, in several cases, these can also be variants resulting from genetic mutations 
associated with early-onset familial forms of the diseases. Even though these familial forms are much 
rarer than the sporadic counterparts and may possibly represent distinct pathologies, their study, both 
in human and in transgenic animal models, has provided a valuable knowledge on the molecular basis 
of the much more widespread sporadic forms (reviewed in [12]). For example, a strong association has 
been shown between the age of the onset of the familial forms and the increase of the aggregation 
propensity of the mutated proteins. Such findings also support the widely accepted link between 
protein aggregation and clinical manifestations of the disease (reviewed in [13,14]). However, the 
structure of the pathogenic species, the molecular basis of their toxicity to cells and the contribution of 
the latter to the overall derangement of tissue function are still the subject of intense debate [15–21].  
In many systemic and CNS amyloidoses, such as AD and Creutzfeldt-Jakob diseases, light chain, 
serum amyloid-A (SAA), dialysis-related amyloidoses and type-II diabetes, the amyloid deposits are 
mainly extracellular and appear as thread-like fibrillar structures, sometimes assembled further into 
larger aggregates or plaques. Yet, in systemic amyloidoses, other components, such as collagen, 
glycosaminoglycans and proteins (e.g., serum amyloid-P (SAP)), are often present in the deposits 
protecting them against degradation [22–24]. However, other conditions (AD, PD and poly(Q) 
diseases, amyotrophic lateral sclerosis (ALS)) are characterized by intracellular protein deposits with 
basic structural features similar to those shown by the extracellular deposits. Intracellular deposits are 
found either in the cytoplasm, in the form of specialized structures, known as aggresomes, in inclusion 
bodies, such as Lewy, Bunina or Russell bodies, or in the nucleus and often arise from deficits in the 
cell’s protective machineries.  
Until the end of 1990s, the idea that mature amyloid fibrils are the key responsible for cell 
impairment and tissue damage provided a theoretical frame to rationalize the molecular basis of the 
known amyloid diseases, as well as to explore therapeutic approaches to amyloidoses mainly aimed at 
hindering growth and deposition of fibrillar aggregates. This view was first questioned in 1998 [15], 
and subsequently, an impressive body of experimental data showed that the aggregation nuclei and 
pre-fibrillar assemblies transiently arising in the path of fibrillization of several peptides and proteins 
and preceding the appearance of mature fibrils are the main toxic entities [16–20,25–29]. The 
increasing importance of these pre-fibrillar aggregates stems from the fact that soluble oligomers 
comparable to those appearing at the onset of fibrillization of several peptides and proteins have been 
repeatedly detected in and purified from, cultured cells and animal tissues, where the monomeric 
precursors are expressed [27–30]. These data have led to establish that amyloid oligomers are really 
formed in vivo, not only in cultured cells, but also in diseased tissue, both in animal models and in 
humans, providing convincing proof that they are really associated with cell/tissue impairment, 
directly contributing to it. 
The awareness that mature amyloid fibrils are substantially devoid of cytotoxicity does not imply 
that they are substantially innocuous. Actually, the huge burden of deposited material in tissue in 
Int. J. Mol. Sci. 2013, 14 12414 
 
several systemic amyloidoses may by itself damage organs simply by hindering a proper flow of 
nutrients to the cells [23]. However, such a notion has led to re-consider, at least in part, the targets of 
the pharmacological strategies aimed at treating the various amyloidoses; in fact, the latter have been 
modified in order to search for molecules able to reduce the accumulation of misfolded proteins, as 
well as their assembly into toxic pre-fibrillar aggregates, rather than at simply hindering their eventual 
growth into mature fibrils. Nevertheless, in some cases, mature amyloid fibrils can affect directly cell 
viability [31–33], whereas in other cases, they can be a source of toxic pre fibrillar species [34,35].  
The different assemblies, from small oligomers to the highly polymeric mature fibrils, appearing in 
the fibrillization process, as in path intermediates or off-path final products, differ remarkably not only 
in their cytotoxic potential, but also in the cellular mechanisms and functions they interfere with. For 
instance, Aβ42 oligomers found in the brains of AD people impair long-term potentiation [17,36] and 
raise endoplasmic reticulum stress [37] and mitochondria derangement [38], whereas the fibrillar Aβ 
deposits appear to be mainly responsible for the tissue neuroinflammatory response [39,40]. Moreover, 
in the case of the Aβ peptides, aggregate cytotoxicity is likely to depend on the aggregation  
state-specific uptake, oligomer toxicity appearing to be associated with oligomer internalization  
by endocytosis [41]. 
The idea that mature fibrils are substantially inert, harmless deposits of the toxic precursors implies 
that their growth has the significance of a cell defense mechanism and contributes toward explaining 
the lack of direct correlation between the load of amyloid plaques in human AD brain and the severity 
of the clinical symptoms [42]. However, up until now, the growing information on the effects of 
amyloids on cell biology has not resulted in any unifying model describing, for all forms of 
amyloidoses, the molecular basis of protein aggregation at physiological conditions, the identity of the 
aggregated species responsible for cell/tissue functional and viability impairment in vivo and the 
molecular mechanism(s) of the latter. In addition, in spite of their recognized importance as main 
cytotoxic entities, a severe lack of information still remains on the structural features of the oligomeric 
assemblies arising transiently in tissue. Actually, at present, it is only recognized that amyloid 
oligomers arising as in-path or off-path intermediates of amyloid fibril growth display increased 
flexibility and an exposed hydrophobic surface with respect to the parent natively folded monomers and 
their final product, mature fibrils. However, in general, these species, when grown at differing 
environmental conditions from the same peptide/protein, can exhibit remarkably variable conformational 
and biophysical features and cytotoxicity, eventually generating fibrils with different properties. For this 
reason, oligomer/fibril polymorphism and its effect on biological systems is a theme of increasing 
interest in amyloid science.  
The search for any therapeutic strategy against amyloid diseases requires a deep knowledge of the 
biophysical and structural determinants of peptide/protein aggregation, of the pattern of aggregate 
growth, of the identification of the species that are responsible for cell/tissue derangement and of the 
mechanisms and molecular basis of the latter. This paper reports some of these issues, providing a 
review of the main data supporting experimentally the anti-aggregation and protective effects of many 
investigated organic and peptidic compounds, with particular emphasis to natural phenolic substances, 
whose anti-aggregation and beneficial properties will be covered in the second part of the review. 
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2. Amyloid Aggregation: Overview and Mechanisms 
In general, protein aggregation into pre-fibrillar and fibrillar assemblies results from  
increased synthesis, reduced clearance, specific mutations, misprocessing, proteolysis or deficits in the 
cellular mechanisms aimed at managing misfolded species and causes derangement of the cellular  
proteostasis [43]. Presently, it is believed that, at least in most cases, both the functional conformation 
of a protein and that leading to aggregation into amyloid fibrils arise from shared precursor(s) 
generated in the folding process and/or arising from some of the states in dynamic equilibrium with the 
folded one. Partially folded states may also appear as a consequence of partial denaturation of the 
native state, resulting from misprocessing, specific mutations, any perturbation of the microenvironment 
(temperature, pH, ionic strength, pressure, shear forces, metal ion or macromolecular concentration) or 
any increase of the concentration of the nucleation precursors above a critical threshold (reviewed  
in [2]). Under these conditions, the partially unfolded molecules display altered tertiary structures, 
while retaining or even increasing the secondary one, as it is the case of some natively unfolded 
proteins that temporarily acquire partially folded conformations [44,45], thus undergoing more or less 
heavy structural reorganization and self-assembly into fibrils [3,4]. In such an ensemble of unfolded or 
partially folded states, hydrophobic groups and main chain amides, normally shielded into the 
compactly folded native state, become exposed to the solvent and can establish new intermolecular 
interactions that foster subsequent growth of large protein aggregates [4]. A balance must therefore 
exist between protein folding and misfolding that normally favors the former and whose alteration can 
contribute to aggregate appearance.  
A protein can be shifted from the folding to the aggregation side of its energy landscape by 
enhancing the factors that more consistently promote aggregation over-folding. In most cases, protein 
aggregation may be triggered by mild destabilization of the medium conditions (a moderate shift of the 
temperature/pH or the presence of low amounts of denaturing agents or of co-solvents) that may 
increase the stability of the secondary contacts, while reducing that of the tertiary interactions in the 
folded protein [46–48].  
The generation of aggregation nuclei at the onset of protein aggregation is considered the  
rate-limiting step of the latter, accounting for the delay times of polymer appearance both in vitro and, 
possibly, in vivo. However, at variance with protein folding, presently, much less is known on the 
conformational states available to an aggregating polypeptide chain and on the structural features at  
the atomic level of the early oligomeric assemblies; several reasons account for this, including 
oligomer instability and broad heterogeneity. In some cases, instead of aggregation nuclei, spherical 
oligomers and other pre-fibrillar forms, including curvy protofibrils, apparently resulting from a 
nucleation-independent path, can be formed in the absence of any lag phase [49–52]. Often, it is  
not clear the difference between oligomers and aggregation nuclei nor whether oligomers are  
on-pathway products, growing by direct recruitment of monomers or off-pathway dead-end reversible 
intermediates [51,53–55]. Finally, a protein can also aggregate by initially populating monomeric or 
oligomeric states, where it substantially maintains its natively folded structure before undergoing 
structural rearrangements into amyloids [56–61].  
As stated in the Introduction, present knowledge considers the early pre-fibrillar species arising in 
the path of amyloid aggregation those endowed with the highest toxicity to cells. A step forward in 
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understanding the molecular basis of amyloid toxicity was made in 2002, when it was first shown that, 
similarly to the tendency to aggregate, also amyloid cytotoxicity could not be considered a specific 
property of the few peptides and proteins found aggregated in amyloid diseases, possibly arising  
from some peculiarity of their specific amino acid sequences; rather, aggregate cytotoxicity appeared  
as a generic feature of the common basic amyloid fold shared by aggregates grown from any 
peptide/protein [20]. Such a knowledge provided further significance to the concept of life on the edge 
between the competing folding and aggregation processes and, hence, between function and 
dysfunction; it also highlighted the importance of the structural and functional adaptations set up by 
protein evolution to favor the functional side of such a border [62]. Actually, the view of protein 
aggregation as a property inherent to the backbone of any polypeptide chain suggests the existence of a 
previously unconsidered constraint in protein evolution; indeed, the latter must have discarded every 
functional sequence with any significant tendency to aggregate under the conditions where its 
biological function is carried out. The generic tendency of polypeptide chains to aggregate also 
underscores the biochemical importance and the biological significance of the complex molecular 
machineries responsible for the quality control of protein folding and for proteostasis. The latter 
include the molecular chaperones, the ubiquitin-proteasome pathway of protein degradation, the heat 
shock response in the cytosol and the unfolded protein response in the ER (reviewed in [63,64]). The 
evolution of such a complex biochemical machinery, as well as of other adaptations aimed at reducing 
the tendency of natural proteins to aggregate, testifies to the key importance, for cells, to avoid the 
appearance and build-up of any potentially aggregating protein or peptide.  
The studies performed in the last few years have established new milestones in the theme of protein 
misfolding and aggregation, providing new clues to the development of effective anti-aggregation 
drugs. Presently, there is increasing awareness that protein aggregation is much more widespread than 
previously believed either in biology or in medicine. Actually, it can expected that the number of 
recognized pathological conditions with amyloid deposits will increase in the future, as has happened 
in recent years [12]. In some cases, amyloids with physiological significance have also been described 
(reviewed in [65]). 
3. Amyloid Aggregates: Mechanisms of Cytotoxicity 
The possibility to develop effective therapeutic or preservation tools to combat amyloid toxicity 
requires a better understanding of the key features of cell/tissue derangement upon exposure to toxic 
amyloids. Deciphering the latter in its complexity and self-reinforcing effects can be quite demanding; 
nevertheless, some basic shared perturbations in the exposed cells have been clearly described. The 
presence of intra- or extra-cellular toxic aggregates can impair a number of cell functions, from 
synaptic transmission and plasticity to cell membrane permeability, mitochondria functioning, ER 
homeostasis, nuclear transcription and cell signaling, eventually leading to cell death by apoptosis or, 
less frequently, by necrosis [66–71]. However, in most cases, initial perturbations of fundamental 
cellular processes appear to underlie the impairment of cell function induced by aggregates of  
disease-associated polypeptides. Increasing information points to a central role performed by 
alterations of the intracellular redox status, synaptic transmission, mitochondria efficiency and free 
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Ca
2+
 levels in cells exposed to toxic aggregates [72–79]; other causes, such as transcriptional 
derangement, have also been proposed [68,80].  
That oxidative stress plays a key role in cell sufferance following exposure to the early aggregates is 
stressed by many experimental data [80–82]. Cell treatment with antioxidants, such as tocopherol, 
lipoic acid, reduced glutathione or phenolic substances, is protective against aggregate toxicity [83–86]. 
Data also point to direct effects of ageing and oxidative stress on cell viability in nerve tissue through a 
reduction of the activity and expression levels of the proteasome [87,88], whose engulfment or 
inhibition are likely to result in the accumulation of oxidized or otherwise damaged or misfolded 
proteins, thus increasing the detrimental effects of reactive oxygen species (ROS) [89]. In this regard, a 
possible role of Hsp27 in preventing polyglutamine cytotoxicity by suppressing ROS production has 
been proposed in cells transiently transfected with vectors expressing exon 1 to produce varying 
lengths of glutamine repeats in huntingtin (htt) [90,91].  
It is not yet clear why protein aggregation is followed by increased ROS production either in the 
cell or in vitro. Specific mechanisms may be involved, as in the case of Aβ42 [92] and α-synuclein  
(α-syn) in dopaminergic neurons in the substantia nigra [93]. The generation of hydroxide radicals 
from hydrogen peroxide by metal ions, such as Fe, Cu and Zn, has also been proposed as a cause of 
oxidative stress [94,95], together with an upregulation of membrane enzymes producing hydrogen 
peroxide (NADPH oxidase, cytochrome P450 reductase [96,97]). More generally, intracellular 
oxidative stress can be related to some form of destabilization of cell membranes by toxic species with 
loss of regulation of plasma membrane proteins, such as receptors and ion pumps [98], and/or 
impairment of mitochondrial function. Mitochondria play a well-recognized role in oxidative stress 
and apoptosis; in this regard, a key factor in Aβ neurotoxicity could be the opening of permeability 
transition pores upon Ca
2+
 entry in neuronal mitochondria [99,100], followed by release of strong 
inducers of apoptosis, such as cytochrome c and apoptosis inducing factor. Intracellular ROS elevation 
following exposure to amyloid aggregates can also be a consequence of Ca
2+
 entry into cells following 
non-specific membrane permeabilization. Increased levels of intracellular Ca
2+
 stimulate the oxidative 
metabolism, providing the ATP needed to support the increased activity of membrane ion pumps 
involved in clearing the excess Ca
2+
 [101]. A similar chain of events could be present in aged tissues, 
where cells are more susceptible to oxidative stress and their energy load is reduced.  
Such a scenario can explain the ROS-Ca
2+
-mitochondrial damage-apoptosis relation described in 
cells exposed to toxic amyloids [78,98–100]. Indeed, many studies support a close involvement of Ca2+ 
deregulation in AD, PD and prion diseases (reviewed in [101]). As pointed out above, increased 
intracellular free Ca
2+
 levels can follow any alteration of membrane permeability, possibly resulting 
from non-specific amyloid pores or other structural modifications provided by cell interaction with 
aggregates or their misfolded monomers. Membrane lipid peroxidation with production of reactive 
alkenals and chemical modification of membrane ion pumps can also contribute to the increase of Ca
2+
 
levels in aggregate-exposed cells [102].  
Similar perturbations of ROS and free Ca
2+
 levels are also found in cells exposed to early 
aggregates of proteins unrelated to disease; even in this case, cell death by apoptosis or, less 
frequently, by necrosis is the final outcome [67,103,104]. The biochemical features involved in the 
different vulnerability of varying cell types exposed to the same toxic pre-fibrillar aggregates have also 
been studied. Significant correlations between cell resistance, total antioxidant capacity and Ca
2+
-ATPase 
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activity were shown in the investigated cell types [105], further underscoring the importance of  
early modifications of free Ca
2+
 and redox status as triggers of the chain of events culminating  
with cell death. Finally, more recent data indicate that the cell membrane biophysical features 
(rigidity/flexibility, polarity, lateral pressure, etc.) resulting from specific lipid composition are very 
important to determine the extent of cytotoxicity of a given type of aggregate [106].  
As outlined before, in most cases, amyloid aggregation implies a first step of aggregate interaction 
with the plasma membrane. Such an interaction may involve generically the bilayer or, in alternative, 
proteins, present in specific membrane areas. In the past, several cell surface proteins have been 
considered as possible candidate receptors for Aβ aggregates, the most investigated in this sense. These 
receptors could be specific for the shared cross-beta fold rather than for any peculiar structural feature 
of the Aβ peptides, although, in some cases, they could also be monomer-specific, as in the Aβ-APP, 
Aβ-TNFR1 or Aβ-PrP interactions proposed to be at the origin of Aβ cytotoxicity [107–109]. Since 
1996, the receptor for advanced glycation end products (RAGE) has been proposed as a major 
candidate as amyloid receptor [110–112]. RAGE transports circulating amyloid-β toxins across the 
blood-brain barrier (BBB) into the brain, and such an interaction leads to oxidative stress, 
inflammatory responses and reduced cerebral blood flow (reviewed in [113]). By competing for ligand 
binding with cell-surface RAGE, its plasma soluble form, sRAGE, might trap circulating ligands 
preventing their interaction with cell surface receptors. Accordingly, regulating RAGE activity at the 
BBB and/or increasing plasma sRAGE are considered promising therapeutic targets to prevent 
vascular damage and neurodegeneration [113,114].  
Several other cell surface proteins, including voltage-gated [115] or ligand-gated calcium channels, 
such as the glutamate NMDA and AMPA receptors [116–118], have also been considered as possible 
receptors or specific interaction sites for amyloids. In addition, tissue-type plasminogen activator (tPA) 
has been proposed as a multiligand specific for the cross-β structure [119]. Finally, increasing evidence 
suggests that additional neuronal binding sites for amyloids, including anionic lipid clusters, such as 
those provided by the presence of GM1 and other gangliosides in lipid rafts, could be present in the 
plasma membrane [120]. Such an idea is supported by the finding that any rise of the content of negatively 
charged lipids results in increased channel formation by amyloids in synthetic lipid bilayers [121]. 
Overall, the specific effects mediated by any preferential oligomer interaction with membrane proteins 
could represent a specific therapeutic target in amyloid diseases.  
That cell viability is impaired similarly by toxic aggregates grown from peptides and proteins 
associated or not associated with amyloid diseases supports the idea that, at least in most cases, a 
common mechanism of cytotoxicity is shared among early aggregates of structurally different peptides 
and proteins; accordingly, the latter are thought to share common structural features in their pre-fibrillar 
organization [122]. Although further studies on a wider range of peptides and proteins are needed to 
explore the generality of these observations, it can be proposed that the cytotoxicity of these types of 
aggregates is generic [20,123], arising from the ―misfolded‖ nature of the aggregated species and their 
precursors with exposure of regions (e.g., hydrophobic residues and the polypeptide main-chain), 
normally buried into the compactly folded native state of the protein. Many of these regions are  
likely to be aggregation-prone (or ―sticky‖) and to interact easily with membranes and other cellular 
components [20,104], thus triggering the complex cascade of biochemical events eventually leading to 
cell death. Recent data on the variable toxicity of different types of oligomers of the same peptide/protein 
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grown at different conditions, and, hence, with different biophysical features (stability, compactness, 
hydrophobic exposure), further underscore that oligomer cytotoxicity is strictly dependent on the 
aggregation conditions and the cell membrane features [106,123].  
4. Amyloid Aggregation Inhibitors: An Overview 
As pointed out above, current research of molecules suitable to counteract amyloid growth and 
toxicity has shifted from hindering growth and deposition of mature fibrils to avoiding protein 
misfolding, with the appearance of the most toxic amyloid assemblies arising at the onset of 
aggregation. The search for treatments able to reinforce the cell defense mechanisms against amyloid 
cytotoxicity (e.g., the ubiquitin-proteasome and the autophagy-lysosome pathways) is also actively 
pursued. Compounds able to counteract amyloid aggregation and aggregate toxicity have been 
particularly investigated for their specific ability (i) to stabilize the amyloidogenic peptides/proteins; 
(ii) to interfere with the aggregation path preventing the appearance of toxic oligomers; (iii) to inhibit 
fibril growth and deposition; (iv) to disassemble preformed fibrils; and (v) to inhibit  
amyloid-membrane interaction. Though the mechanism of action of most potential inhibitors is often 
still unclear and their effects can vary depending on the conditions in which they are assayed (i.e., 
target amyloidogenic protein, protein/inhibitor molar ratio, pH, temperature, buffer, interfaces, and so 
on), efforts have been made to organize the existing knowledge. Accordingly, a classification of 
amyloid inhibitors into three main categories has been proposed: Class I molecules, inhibiting amyloid 
oligomerization, but not fibrillization; Class II molecules, inhibiting both oligomerization and 
fibrillization; and Class III molecules, inhibiting fibrillization, but not oligomerization [55]. This 
classification does not take into account the mechanism of inhibition; instead, it simply refers to the 
final outcome of the process. This means that, as we will see in the next sections, different inhibitors 
can be inserted in the same class though their molecular mechanism of action is substantially different. A 
large number of natural or synthetic molecules have been investigated for any of these effects, including 
peptide analogues or variants, peptoids, beta-breaker and cyclic peptides and other peptidic  
compounds [124–129], antibiotics [130–134], non-steroidal anti-inflammatory compounds [135], 
antibodies [122,136], many organic substances [137–143] and dyes [144–146], cyclodextrins [147] 
nanoparticles [148,149], nanomicelles and surfactants [150,151], small molecule colloidal  
aggregates [152], organofluorine compounds [153], natural phenolic substances (see later) and  
many others. 
Stabilization of peptides and proteins precursors of aggregate growth can be a strategy exploitable 
at least in some cases. An example is stabilization of transthyretin (TTR) tetramer disfavoring its 
dissociation in unstable dimers/monomers that can easily undergo aggregation. In this sense, substances 
that mimic the stabilizing effect of the natural ligand, T4, have been investigated [154–156], and some 
of them (doxycycline, diflunisal, mds84, tafamidis) have entered clinical trial [157,158]. Another 
strategy was aimed at finding substances able to disrupt amyloid deposits, as it is the case of several 
tetracyclines, such as doxycycline [159]; even in this case, clinical trials are underway [160]. 
Tetracyclines and some analogues may also be useful to inhibit aggregate formation [132,138]. 
Antibodies may be effective against aggregate nucleation, can stabilize the highly unstable and toxic 
oligomers, hinder their growth into higher order polymers and mature fibrils and favor aggregate 
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clearance [122,161–163]. These effects are at the basis of the proposed immunotherapy of AD and, 
possibly, of other diseases [164]. Other inhibitors of amyloid aggregation may act by providing an 
unfavorable surface in a two-phase system. The latter include nanoparticles with surface chemical 
properties favoring strong absorption of the peptide/protein [148,149]; colloidal micelles and 
surfactants may also adsorb strongly monomeric peptides/proteins, avoiding their reciprocal interaction 
into aggregation nuclei in a way that resembles that displayed by molecular chaperones [150,151]. 
Curiously, many fibrillization inhibitors recall molecules known to form colloidal particles formed by 
promiscuous chemical aggregates 50–600 nm in size [165]. Once formed, they physically sequester 
proteins and inhibit enzymes nonspecifically [165,166]. Like many inhibitors of amyloid polymerization, 
these colloidal inhibitors are typically highly conjugated, hydrophobic and dye-like, as is the case of 
Congo red [165], some flavonoids [167] and other organic molecules [168]. The problem with most of 
the substances listed above is that they cannot be proposed for therapeutic use, and their anti-aggregation 
effects are merely of scientific interest, providing information to better explain the molecular mechanism 
of protein/peptide aggregation and to search molecular scaffolds with enhanced anti-amyloid properties.  
Molecular mechanisms similar to those listed above also apply for natural phenolic and polyphenolic 
substances that have been shown to stabilize native states [169,170] or to remodel and inactivate toxic 
amyloid oligomers by several mechanisms [171–173] that may differ depending on whether they are 
glycated or not [174]. Natural phenolic substances display at least an advantage over most of the 
molecules mentioned above: they are of natural origin, are present in many foods and are usually 
assumed by humans with the diet in variable amounts and more or less continuous way. Such an aspect 
is of particular interest and may contribute to explain the anti-aging effects of many polyphenols 
(reviewed in [175]), as well as the results of many epidemiological studies showing a significantly 
reduced incidence of age-related diseases, particularly neurodegenerative conditions, such as AD and 
PD, in population with specific dietary regimens, including the so-called Mediterranean diet (MD), 
where some of these substances are present at relatively high concentrations [176–178]. 
The following section will revise the most investigated natural phenols and the information 
gathered in recent years on their effect against amyloid aggregation and their possible use as 
nutraceuticals or in therapy. 
5. The Anti-Amyloid Properties of Natural Phenols and Polyphenols 
5.1. Curcumin 
Curcumin (Cur) ((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), a diphenol 
(Figure 1) is the major component of turmeric, a spice derived from the rhizome of Curcuma longa. 
Figure 1. Curcumin structure. 
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Turmeric has a long history of use in traditional medicines in China and India [179]; where it is also 
used as a curry spice in foods. Interestingly, people in India, in spite of a shorter lifetime  
expectation, present a lower incidence of AD with respect to the US (0.7% vs. 3.1% in patients 
between 70 and 79 year old; [180]), and curry consumption in old age has been associated to better 
cognitive functions [181].  
The extended and conjugated symmetric structure of Cur resembles that of Congo Red, a dye that 
interferes with the aggregation process [144], binds amyloid aggregates and stains amyloid deposits  
in vivo [182]. After the first evidence of a possible efficacy of Cur against AD coming from a study 
carried out with the AD transgenic mouse model Tg2576 [183], its power as an inhibitor of amyloid 
aggregation has been actively investigated in vitro. The use of the classical Thioflavin-T (ThT) binding 
assay to follow the kinetics of amyloid aggregation in the presence of Cur is questionable, though 
frequently used, due to the superimposition of Cur and ThT fluorescence emission spectra [182] and to the 
ability of Cur to compete with ThT for fibril binding [184]. Anyway, the efficacy of Cur both as an 
inhibitor of Aβ amyloid aggregation and as a fibril destabilizer was soon confirmed by transmission 
electron microscopy (TEM) analysis and dot blot assay of toxic oligomers by using the A11  
antibody [182,185]. Subsequently, Cur efficacy as a general inhibitor of amyloid aggregation was 
tested on several proteins associated with amyloid diseases, unrevealing both common and specific 
features. In fact, according to the classification proposed by Necula et al. [55], Cur works in some 
cases as a Class I inhibitor (inhibiting amyloid oligomerization, but not fibrillization), in some others 
as a Class II inhibitor (inhibiting both oligomerization and fibrillization) and, in the case of TTR 
mutants, as a Class III inhibitor (inhibiting fibrillization, but not oligomerization). In this case, recent 
work has shown that Cur binds to wt and mutant TTR, increasing its conformational stability both  
in vitro and ex vivo, and interferes with the aggregation cascade, redirecting it toward the formation of 
non-toxic off-pathway intermediates (see below) [186,187]. 
Cur activity towards Aβ42, hen egg-white lysozyme (HEWL) and human insulin amyloidogenic 
polypeptide (hIAPP) belongs to the first category of inhibitors: Cur inhibits Aβ42 peptide oligomerization, 
promoting the deposition of fibrils in vitro and in vivo [188,189], and counteracts HEWL aggregation, 
affecting also preformed fibrils, determining, in both cases, the formation of short, sheared fibrillar 
species [190]. While the fibrillar aggregates that are formed by Aβ and HEWL in the presence of Cur 
are devoid of cytotoxicity [182,191], this seems not to be the case for hIAPP: circular dichroism (CD) 
and nuclear magnetic resonance (NMR) analyses reveal that Cur inhibits the structural transition of 
hIAPP to the α-helical intermediate and slows down the aggregation kinetics, but it neither inhibits the 
deposition of short fibrils nor disaggregates β-sheet assemblies of hIAPP [192] and, while partially 
relieving exogenous hIAPP toxicity to INS cells, fails to protect against cytotoxicity in either INS cells 
overexpressing hIAPP or hIAPP transgenic rat islets [193]. 
Cur seems to behave like a Class II inhibitor towards α-syn and PrP aggregation. In fact, it increases 
the solubility of α-syn monomers preventing protein oligomerization dose-dependently and reducing 
also the amount of high molecular weight aggregates once added to preformed fibrils [194]. In the case 
of PrP, Cur binds to its acidic α-helical intermediate, to β-sheet oligomers and fibrils (but not to native 
PrP), as suggested by the increase of the intrinsic fluorescence of Cur in the presence of PrP and by the 
induced CD spectrum of Cur, reducing the extent of PrP oligomerization and fibrillation [195]. 
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Cur interacts with TTR by competing with T4 for its binding site and stabilizes its tetrameric native 
state, thus inhibiting fibril formation by TTR aggregation-prone mutants, disaggregating preformed 
fibrils and determining the formation of small off-pathway non-toxic oligomers, as shown by TEM, 
dot blot, dynamic light scattering (DLS) analysis and by caspase-3 activity determination in exposed 
cultured cells [186]. In addition, dietary Cur administration to the hTTR mice model expressing mutant 
V30M TTR results in potent competition with T4 for TTR binding and in a significant inhibition of 
tetramer dissociation into non-native monomeric intermediates, decreasing TTR deposition in tissues 
and reducing Fas-death receptor, ER-resident chaperone BiP and 3-nitrotyrosine levels in the vicinity 
of the deposits [169]. These properties depict an effect of Cur as a TTR stabilizer, which recalls that of 
a number of drugs presently under clinical trial (see above).  
The observation that the Cur anti-aggregation power results in different outcomes suggests both 
different molecular mechanisms and common features of inhibition. Evidence suggests that Cur generally 
binds the target protein/peptide, as shown by the increase of its intrinsic fluorescence in the presence of 
amyloidogenic proteins [195,196], and by its ability to stain amyloid deposits in vivo [182,194], 
similarly to ThT and Congo Red, even though the fate of the complex varies, depending, in particular, 
on the initial state of the protein. Cur seems to inhibit both oligomerization and fibrillization when it 
interacts with the protein monomer in its native form or at the very beginning of its structural 
transition. In the case of PrP, Cur fluorescence assays reveal that it binds, with a stoichiometry close to 
1:1, to the monomeric intermediate, which displays a predominantly α-helical structure and molten 
globule features, thus preventing its conversion to the amyloidogenic β-sheet rich form. Moreover, the 
analysis of the CD spectrum of Cur in the presence of preformed PrP oligomers and fibrils suggests 
that one Cur molecule binds to a PrP dimer (the amyloid building block), possibly intercalating 
between neighboring PrP subunits, thus preventing fibril growth [195].  
In the case of α-syn, the determination by the Trp-Cys contact quenching method of the rate of 
intramolecular diffusion of the α-syn monomer in the presence or in the absence of Cur provided 
interesting clues on the mechanism of inhibition of fibril growth [197]. Intramolecular diffusion is the 
random motion of one part of the protein relative to another. When it is fast, compared to the rate of 
bimolecular association, aggregation is unlikely, because exposed hydrophobic groups quickly 
reconfigure, whereas when it is slow, aggregation is favored. Cur binds strongly to the α-syn 
monomer, with a dissociation constant of 10
−5
 M, and disrupts the long-range interactions inside the 
peptide chain, increasing the reconfiguration rate of the molecule, thus completely inhibiting both 
oligomerization and fibrillization. 
For what Cur interaction with the Aβ peptide is concerned, its effect on the stability of the Aβ dimer 
was examined by means of all-atom explicit solvent simulations [198], revealing that Cur acts as an 
efficient β-sheet breaker, while maintaining the contacts between monomers. This can be the reason 
why it inhibits the structural transition, leading to the formation of toxic oligomers, but does not avoid 
protein aggregation. The π-stacking between Cur and Aβ aromatic rings was maintained throughout 
the whole simulation, suggesting it is an important component of the interaction and a key player of 
Cur inhibitory activity. The frequent π–π stacking interactions between Cur aromatic rings and the 
aromatic side chains of His, Tyr and Phe, though transient, would contribute indirectly to a reduction 
of the β-sheet content in the Aβ dimer. Another computational study suggested that, in Cur, the enolic 
center and the two phenolic acidic groups separated by a substantially hydrophobic bridge would 
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provide to the molecule both hydrophobic and hydrophilic features; of these, the former could facilitate 
Cur penetration into the BBB, and the latter could favor subsequent binding to Aβ oligomers [199]. 
These ideas on the importance of the Cur structural features have been validated by solid state NMR 
experiments, showing that in Cur, the methoxy and hydroxyl groups adjacent to the aromatic carbons 
are involved in the Cur-Aβ interaction [200]. These data were confirmed by a study carried out with 
several Cur synthetic analogs, further suggesting that the carbon spacer between the two aryl rings 
must contain an enone group to ensure the anti-amyloidogenic activity [201]. The integration of these 
results with those obtained by Reinke et al. [202] by using another library of Cur analogs and the Aβ42 
peptide led to hypothesize that a fairly rigid unsaturated, 8–16 Ǻ-long, carbon chain provides the  
best linker to accommodate the aromatic rings in two distinct (yet unidentified) binding sites on the 
target peptide. 
In spite of its reduced bioavailability (3.6 mmol/kg body weight are required to obtain detectable 
tissue levels in rats [203]), Cur has been reported to cross the BBB and to label amyloid plaques in AD 
model mice with various outcomes: in some cases, it reduces plaque burden; in some others, 
coherently with in vitro studies, it reduces A11-positive oligomers, while unaffecting plaque 
deposition (for a review see [204]). Up until now, clinical trials carried out on humans affected by AD 
or by mild cognitive impairment have not provided results corroborating Cur efficacy, but several 
studies are still ongoing (for a review, see [205]). 
5.2. Epigallocatechin-Gallate 
(−)-Epigallocatechin-3-gallate (EGCG) (Figure 2) is a member of a family of flavan-3-ols and the 
most abundant polyphenol in green tea extracts.  
Figure 2. EGCG structure. 
 
Initially, EGCG protection against Aβ toxicity to cultured hippocampal neurons was attributed 
essentially to its antioxidant activity [206]. Later on, EGCG was shown to reduce both Aβ production 
in cultured cells and Aβ-amyloid plaque deposition in transgenic mice expressing the ―Swedish‖ APP 
mutant, by promoting the non-amyloidogenic α-secretase proteolytic pathway [207]. A study aimed at 
investigating the association between green tea consumption and cognitive function in elderly Japanese 
subjects showed that a higher consumption of this beverage was associated with a lower prevalence of 
cognitive impairment in humans [208]. A contribution of the EGCG iron chelating property, resulting 
in modulation of APP translation via an IRE (IRE type II) present in the 5'-UTR region of APP, was 
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also considered of importance [209]. At the same time, EGCG was shown to interfere directly with 
amyloid fibril formation from several peptides and proteins and to remodel preformed fibrils, thus 
generating non-toxic species. The investigated peptides/proteins include Aβ, α-syn, mutant htt,  
TTR, hIAPP, the amyloidogenic peptide PAP248–286 from prostatic acidic phosphatase (that aggregates  
into fibrils known as semen-derived enhancer of virus infection–SEVI), HEWL, k-casein and 
calcitonin [210–218]. 
The study of the molecular features of EGCG interaction with amyloidogenic peptides/proteins 
disclosed two different modalities that also corresponded to different outcomes in terms of inhibitory 
activity and final products: (i) EGCG binds to the unfolded or misfolded peptide/protein with  
non-covalent random interactions involving the peptide backbone and redirects aggregation towards 
the formation of small off-pathway oligomers or amorphous material; and (ii) EGCG binds to the 
native form of the peptide/protein through interactions with the side-chains of specific residues that 
maintain peptide/protein native configuration preventing its aggregation. The first pattern of inhibitory 
activity is displayed by EGCG towards α-syn, Aβ, htt, hIAPP and HEWL [212,219–221]. In the case 
of α-syn and Aβ, EGCG stimulates the assembly of amorphous material and of spherical  
SDS-resistant oligomers that are not recognized by the A11 antibody and have no seeding properties; 
for these reasons, these assemblies are considered off-pathway with respect to the fibrillization  
process [219]. EGCG also remodels Aβ and α-syn mature fibrils and toxic oligomers into non-toxic 
small protein aggregates, without fibril depolymerization, determining a loss of β-sheet content [222]. 
This implies that EGCG binds to unfolded monomers, oligomers and fibrils, as confirmed by the nitro 
blue tetrazolium (NBT) staining assay. It was initially suggested that EGCG inhibits the 
conformational transition of Aβ from a random coil to the amyloidogenic β-sheet structure, thereby 
favoring the deposition of unstructured aggregates [219]; however, recent solid-state NMR analysis 
indicates that the small oligomers formed in the presence of EGCG show defined correlation signals, 
suggesting that they are not amorphous, but significantly structured, though unable to seed further 
fibril growth and devoid of toxicity [223]. A very recent study conducted on Aβ40, hIAPP and the 
Sup35NMAc7–16 Y→F mutant showed that hydrophobic interaction of the oxidized form of the 
polyphenol with the peptide is mainly responsible for EGCG remodeling activity [224]; when free 
amines or thiols are proximal to the EGCG hydrophobic binding sites, the EGCG-based quinones are 
then capable of covalently modifying the amyloidogenic proteins through Schiff base formation, but 
this is not a pre-requisite for amyloid remodeling. 
The thermodynamics of the EGCG-Aβ interaction were studied by isothermal titration  
calorimetry [225]; in the 25–45 °C range and at EGCG:Aβ ratios <16, such an interaction is  
enthalpy-driven and, hence, mainly dependent on hydrogen bonding (hydrophobic interactions are 
entropy-driven, but entropy decreases during the process, so they do not seem to be involved).  
EGCG-Aβ interaction is favored by pH values either lower or higher than the Aβ pI (pH 5.0): at both 
conditions the formation of hydrogen bonds between EGCG and Aβ is favored. Thermodynamic 
analysis further reveals that when the EGCG:Aβ ratio is in the 16–46 range; the interaction is favored 
by both a decrease of enthalpy and an increase of entropy, indicating important roles of both hydrogen 
bonding and hydrophobic interactions. When the EGCG:Aβ ratio rises over 46, entropy becomes the 
only driving force, suggesting a predominant contribution of the hydrophobic interactions. The ΔG 
values at different solution conditions are essentially invariant, since the hydrogen bonding (mainly 
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involving the Aβ1–16 region) and the hydrophobic interaction (mainly involving the Aβ17–42 region) 
change in opposite ways, compensating for each other and ensuring EGCG binding to Aβ over a broad 
range of solution conditions [226]. 
The predominance of the interaction of EGCG with the peptide backbone characterizes its action on 
hIAPP. EGCG was found to be still effective in inhibiting the aggregation of hIAPP mutants lacking 
the best candidate sites for interaction with a polyphenolic ligand, namely the three conserved aromatic 
residues, the disulfide group and the free amino group. By a process of elimination, the authors concluded 
that EGCG interacts with hIAPP by hydrogen bonding to the peptide backbone and by relatively  
non-specific (presumably hydrophobic) interactions of the gallate ester with side chains [220]. The 
fundamental role of the gallate ester in the anti-aggregation power of EGCG was further confirmed by 
showing that (−)-gallocatechin, (−)-epigallocatechin and epicatechin display reduced efficacy (or total 
inefficacy) against htt, Aβ, α-syn, HEWL and hIAPP aggregation [216,222,227]. 
The importance of hydrophobic interactions in the inhibitory activity of EGCG towards hIAPP 
aggregation was confirmed by both Palhano et al. [224] and Engel et al. [228], but while the former 
showed that the polyphenol was still able to disaggregate hIAPP fibrils in the presence of detergent 
micelles, the latter demonstrated that in the presence of a DPPG monolayer EGCG anti-aggregating 
activity towards hIAPP was much reduced and its ability to disaggregate preformed fibrils completely 
suppressed, due to the polyphenol inability to access the binding sites on the peptide and, possibly, to 
its sequestration by the lipid interface [228]. In light of the importance of membrane damage in the 
context of amyloid toxicity and considering the general ability of polyphenols to interact with 
membranes, thus changing their physical properties [229,230], this topic deserves further investigation, 
using standardized experimental conditions.  
EGCG inhibits TTR, SEVI and k-casein aggregation by stabilizing their native  
conformations [217,222,231]. This was confirmed for TTR by treating with EGCG a familial 
amyloidotic polyneuropathy (FAP) mouse model expressing human V30M TTR. In this model, an 
increase of serum TTR tetramer stability was observed, accompanied by a reduction of TTR 
congophilic deposits [168,186]. In vitro studies showed that EGCG binds to both wt and mutant TTR, 
as it is evident by NBT staining, forming an SDS-stable adduct with a 1:1 molar ratio, as confirmed by 
MS analysis. Such interaction does not involve the T4 binding site and stabilizes the native tetramer, 
thus inhibiting aggregation. EGCG is also able to destabilize preformed TTR fibrils, generating small 
polydispersed amorphous aggregates [186,222]. The crystal structure of the EGCG-V30M TTR 
complex has shown that EGCG binds specific residues at the interface between two TTR monomers, 
thus stabilizing the tetramer. EGCG can also induce the association of two TTR tetramers (both wt and 
mutant) into small oligomers that are non-toxic to IMR-32 neuroblastoma cells [232]. Even in this 
case, similarly to Cur, EGCG appears to behave in a way that recalls that of drugs currently under 
clinical trials as TTR stabilizers (see above). 
The association between EGCG and PAP248–286 (the prostatic acid phosphatase fragment that 
aggregates into SEVI fibrils [231]) is also characterized by the interaction with specific amino acid 
residues; the interaction inhibits fibril formation and leads to fibril depolymerization both at neutral 
and mildly acidic pH (typical of vaginal fluid). NMR and electrospray ionization-mass spectrometry 
(ESI-MS) analysis together with the NBT assay suggested that EGCG binds monomeric PAP248–286 
through a multistep process: initially, a weakly bound noncovalent complex is formed, where most 
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likely hydrogen bonding and hydrophobic interactions predominate; subsequently, after the generation 
of a reactive quinone complex by EGCG auto-oxidation, a covalent complex arises through Schiff base 
addition involving lysine side chains [231]. 
RCMκ-CN (reduced and carboxymethylated κ-casein), a non-disease-associated natively-disordered 
amyloidogenic protein, was used as a peptide model to investigate the EGCG anti-aggregation activity. 
Although predominantly unfolded, RCMκ-CN contains a large antiparallel β-sheet region that requires 
little conformational change to aggregate, forming the cross-β-sheet core of mature RCMκ-CN 
amyloid fibrils. Furthermore, in this case, EGCG (in a 1:1 molar ratio with RCMκ-CN) was shown to 
constrain the protein in its micellar native-like state, rather than redirecting its aggregation path 
towards the formation of amorphous deposits [217]. NMR experiments demonstrated that EGCG 
suppresses RCMκ-CN fibril formation by interacting with its relatively rigid amyloidogenic β-sheet 
region through strong SDS-stable hydrophobic associations and, possibly, π–π stacking interactions 
with aromatic residues. 
For what the possible pharmacological use of EGCG is concerned, most of the ingested EGCG does 
not get into the blood: absorption takes place in the small intestine, but substantial quantities pass to 
the large intestine to be eliminated [233]. The conditions that seem to increase EGCG plasma levels 
are administration after an overnight fasting period together with 200 mg ascorbic acid and 1,000 mg 
salmon omega-3 fatty acids, without caffeine [234]. Omega-3 polyunsaturated fatty acids seems to 
enhance oral bioavailability of EGCG and also to improve its efficacy [235]. 
5.3. Resveratrol 
Resveratrol (3,5,4'-trihydroxystilbene) is a non-flavonoid polyphenol that occurs in several foods 
and is particularly abundant in the skin and seeds of the grape’s fruit (Vitis vinifera) and in red wine 
(Figure 3).  
Figure 3. Resveratrol structure. 
 
Resveratrol is a member of the stilbene family, a group of compounds that consist of two aromatic 
rings joined by a methylene bridge. It has attracted great attention, since it was considered responsible 
for the cardioprotective effects of red wine, resulting in a low incidence of cardiovascular diseases in 
the French population despite a diet rich in saturated fats (the so-called ―French Paradox‖). Such 
protection comes from the ability of red wine and grape extract to reduce platelet aggregation, uphold 
vasorelaxation, prevent atherosclerosis, decrease lipid peroxidation and ameliorate serum cholesterol 
and triglyceride concentrations [236]. 
Since the first study, published in 1997, reporting that moderate-to-mild wine consumption  
was associated with a low risk of AD [237], both epidemiologic studies and experimental treatment  
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of animal models have shown that resveratrol may be a powerful agent preventing β-amyloid 
deposition-associated neurodegeneration [238–240]. Accordingly, several attempts are being made to 
design resveratrol derivatives with enhanced protective properties [241] and to improve its bioavailability, 
for example, by using lipid-core nanocapsules [242,243]. The biochemical mechanism of resveratrol 
protection is multifaceted; besides its antioxidant activity [244], it involves modulatory effects on 
several pathways that were investigated particularly in the context of Aβ toxicity. It was shown to 
reduce both intracellular and secreted Aβ in cell culture by promoting its proteasome-dependent 
degradation [245]; to reduce Aβ-stimulated death signals, such as NF-κB signaling and p53 activity, by 
activating SIRT-1 and mimicking the effect of caloric restriction [246,247]; and to increase AMPK 
activity, thus triggering the autophagic degradation of Aβ aggregates [248]. These (and other) pieces of 
evidence support the hypothesis that resveratrol acts upstream of one (or more) signaling cascades, 
possibly triggered upon binding to a membrane receptor. Actually, potential binding sites widely 
distributed in rat brain were detected in the plasma membrane and, to a lesser extent, in nuclear and 
cellular fractions of rat brain homogenates [249]. 
Most notably, resveratrol is also able to directly interfere with the amyloid aggregation of different 
peptides, reducing their toxicity, as is the case for hIAPP [250]. By X-ray reflectivity measurements, it 
was also shown that resveratrol inhibits hIAPP interaction with a lipid layer interacting preferentially 
with peptide monomers [251], a particularly valuable effect, considering that hIAPP fibrillization at  
the cell membrane and subsequent membrane destabilization are important determinants of hIAPP 
toxicity [252]. Fluorescence microscopy analysis further suggested that resveratrol redirects hIAPP 
aggregation towards the formation of amorphous non-toxic aggregates that do not interact with INS-1E 
cells [253], and following NMR analysis, it was proposed that resveratrol binds to hIAPP His-18, 
thereby inhibiting early formation of oligomeric intermediates [254]. 
Resveratrol was shown to dose-dependently inhibit the Aβ peptide fibrillization and to depolymerize its 
preformed fibrils, in both cases leading to the formation of non-toxic oligomers [255]. Actually, 
resveratrol seems to remodel a subset of Aβ conformers that possess random coil (A11-positive soluble 
oligomers, but not non-toxic oligomers) or β-sheet (OC-positive fibrillar intermediates and fibrils) 
structures into SDS-resistant, non-toxic, unstructured conformers [172]. The direct interaction of 
resveratrol with Aβ monomers and fibrils was confirmed by surface plasmon resonance (SPR) and 
NMR analysis [256]. 
X-ray structure analysis showed that resveratrol forms a complex with TTR, where it fits the T4 
binding site by non-polar contacts mediated by the stilbene moiety, reinforced by hydrogen bonds 
involving its hydroxyl groups, thus preventing protein aggregation [257]. 
Resveratrol can also inhibit lysozyme aggregation and depolymerize pre-formed fibrils [258]. An 
interesting study carried out on this polyphenol (and on a panel of different phenolic substances) 
showed that its glycosidic and aglycone forms remodel A11-positive Aβ oligomers and OC-positive 
fibrils through different pathways: while the aglycone remodels the oligomers into large aggregates, 
the glycoside (named piceid) disaggregates them, releasing the soluble peptide. From these results, it 
was hypothesized that the aglycone moiety of polyphenols disrupts those intermolecular contacts that 
involve aromatic groups, leading the newly exposed aromatic residues to associate with the sugar 
moiety (when present); accordingly, other intra- and inter-molecular associations are prevented, and 
the formation of amorphous aggregates is avoided. Structure comparison analysis suggest that, in 
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polyphenols, the number of phenolic rings is the primary determinant of the remodeling efficacy and 
that the minimal structural requirement for phenolic aglycones to remodel Aβ oligomers consists in 
two aromatic rings, of which at least one must possess an hydroxyl moiety [174]. 
5.4. Quercetin and Myricetin 
Quercetin (3,30,40,5,7-penta-hydroxyflavone) and myricetin (3,3',4,5,5',7-hexahydroxyflavone) 
(Figure 4) are flavonols found in many foods of vegetal origin, including tea, onions, cocoa and red 
wine, and in Ginkgo biloba EGb 761 extract.  
Figure 4. Myricetin and quercetin structure. 
 
 
 
Unlike the phenols described in the previous paragraphs, these substances were initially 
investigated for their anti-amyloidogenic activity in vitro and only subsequently tested for their 
efficacy in vivo. By ThT binding and TEM analysis, they were shown to prevent the growth of  
Aβ amyloid aggregates in vitro and to destabilize preformed fibrils [185]. In a study carried out on 39 
flavonoids, the strong inhibitory effects against Aβ fibrillation of the flavones were outlined, and 
quercetin was shown to be one of the most potent representatives of this category (IC50 = 2.4 μg/mL), 
providing also cell protection against Aβ cytotoxicity [259]. It was suggested that the 3-hydroxy, 4-keto 
groups of flavonols are essential for inhibition of Aβ fibril growth, but a subsequent study reached 
different conclusions, showing that the 3-hydroxyl group is not necessary, while the 3',4'-dihydroxyl 
group of the B ring is essential [260]. Whatever the case, there is consensus on the assumption that 
increasing the number of hydroxyl groups on the B ring improves the anti-aggregation effect of 
flavonoids; in fact, myricetin, which contains an additional hydroxyl group, is more effective than 
quercetin against Aβ aggregation [261]. Quercetin (like other flavonols) was also shown to heavily 
quench ThT fluorescence emission [184], so all the conclusions concerning the in vitro anti-amyloidogenic 
activity of flavonols must be supported by further experimental pieces of evidence.  
Quercetin and myricetin efficacy as amyloid aggregation inhibitors and preformed fibril destabilizers 
was confirmed with insulin and α-syn, respectively [262,263]; yet, other compelling results were also 
reported: Jagota et al. [264] suggested that quercetin inhibits Aβ fibrillization, but not its toxic 
oligomerization, hence increasing Aβ toxicity in a C. elegans model of Aβ deposition; Noor et al. [265] 
reported that quercetin and myricetin were not able to prevent hIAPP fibrillation, at variance with 
morin (which differs only for the position and/or the number of the hydroxyl groups on the B ring). 
However, they did not investigate the possible effects of the two flavonols either on the most harmful 
oligomeric species or on aggregate toxicity. Actually, myricetin was later shown to dose-dependently 
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inhibit hIAPP toxic aggregation [266]. The way both flavonols inhibit amyloid aggregation is still a 
matter of debate, as well, even considering their activity on the same amyloidogenic peptide. In fact, 
data obtained by SPR analysis and fluorescence spectroscopy of the compounds in their free or bound 
state led to speculate that they would preferentially bind to Aβ fibrils, not to monomers, particularly to 
the fibril growing ends, competing with monomers for binding and inhibiting fibril elongation, 
behaving as Class II inhibitors [267]; the opposite was found, by treating the Tg2576 mice model of 
AD with myricetin, where a decrease of A11-positive oligomers with no change of plaque burden was 
observed, suggesting that, rather, it would act as a class I inhibitor. The data agree with an in vitro 
study showing that myricetin could hamper Aβ oligomerization, but not fibrillization [55,188]. Finally, 
electrospray ionization-ion trap mass spectrometry (ESI-IT MS) analysis of Aβ monomers revealed 
their prolonged persistence in the presence of myricetin, even at aggregation conditions, indicating that 
myricetin targets preferentially Aβ monomers and short transient oligomers, thus lowering the 
aggregation rate and reducing fibrillization, also. These data support the idea that myricetin behaves as 
a Class III inhibitor [268]. Moreover, other MS analysis suggested that myricetin could exert a  
pro-oxidant activity on Aβ Met35, hindering the amyloidogenic conformation [269]. However, this 
assumption was not validated by NMR studies, which confirmed preferential binding of myricetin to 
localized regions of monomeric Aβ, hindering oligomerization and reducing synaptoxicity [270].  
Overall, these and other data indicate that, at present, there is not a consensus on the molecular 
features of the myricetin anti-amyloidogenic power. However, the subject is being actively 
investigated; computational analysis performed on Aβ GNNQQNY fragment oligomers suggested that 
myricetin forms H-bonds with the surface of the β-sheet, weakening the interstrand hydrogen bonds 
and disaggregating the outer layer of the aggregate [271], while CD and deep-ultraviolet resonance 
Raman spectroscopy supported the importance of the aromatic interactions [272].  
Besides a direct inhibitory effect on amyloid aggregation, quercetin and myricetin seem to exert a 
general protection against amyloid-induced cytotoxicity acting at multiple levels. In fact, they inhibit 
β-site APP cleaving enzyme-1 (BACE-1) activity [273], scavenge ROS [274–276] and also behave as 
competitive inhibitors against the oxidative activity of the complex Aβ-Cu2+ by interacting with the 
metal binding site on Aβ via their α-keto enolate group, thus maintaining the integrity of their catechol 
moiety with a resulting bifunctional inhibitory activity (metal chelation and Aβ interaction) against 
amyloid aggregation [277,278].  
Quercetin also activates AMPK, thus triggering a pleiotropic neuroprotective cascade [279], enhances 
neurogenesis and synaptogenesis through a CREB phosphorylation-mediated signaling pathway [280] 
and hinders the interaction of amyloidogenic peptides with membranes and their permeabilization by 
inserting between the outer part of the hydrophobic core and the external hydrophilic layer of the lipid 
bilayer [281]. Finally, myricetin relieves glutamate-induced neuronal toxicity by multiple pathways 
(N-methyl-D-aspartate receptor modulation and reduction of intracellular Ca
2+
 overload, inhibition of 
ROS production, reduction of caspase-3 activation) [282] and inhibits Tau filament formation [283].  
5.5. Olive Oil Phenols 
Olive oil phenols have attracted more and more attention since, together with resveratrol (see 
above) and other phenols, they are typical components of the so-called MD that, among others, is 
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believed to provide significant protection against mild cognitive impairment and its conversion to  
AD [176]. Studies in rodents suggest that diet supplementation with extra virgin olive oil (EVOO) 
improves learning and behavioral deficits associated with aging and disease [284,285]. In addition, 
several reports, including the ―Three city study‖ [286], support a strict association between many 
protective effects of the MD and the sustained assumption of EVOO. The phenols most abundant in 
the EVOO and most investigated for their ability to prevent amyloid aggregation and its toxic effects 
both in vitro and in vivo are oleuropein aglycone and oleocanthal. 
Oleuropein is a secoiridoid and can be considered the ester between hydroxytyrosol and the 
glucosidic form of elenolic acid. It is deglycosylated by a β-glucosidase released from olive fruits 
during crushing, giving rise to oleuropein aglycone (OLE) (Figure 5), which, due to its high 
hydrophobicity, is retrieved in oil [287].  
Figure 5. Oleuropein and oleuropein aglycone (OLE) structures. 
 
The content of OLE in olive drupe depends on the cultivar [288,289] and the time of ripening; in 
addition, the recovery of the deglycosylated oleuropein derivative depends on the way the fruits are 
processed to obtain EVOO [290]. Finally, the content of OLE in EVOO depends on oil ageing, as the 
molecule undergoes degradation (mainly oxidation) with time [291]. 
Oleuropein can associate to the monomeric form of Aβ40 and AβMet35(O) with a 1:1–2:1 
stoichiometry; such an interaction is non-covalent, but possesses a remarkable binding energy, since  
the complexes are still observable when an orifice potential of 100 V is applied to the ESI-MS 
apparatus [292,293]. Through enzymatic cleavage of the Aβ:oleuropein complex prior to ESI-MS 
analysis, three peptide segments were identified as being implicated in the interaction; of these,  
the hydrophobic (17–21) one is the best candidate to interact with the non-polar moiety of  
oleuropein [293] and, hence, also with its aglycone derivative. Interestingly, the Aβ sequence critical 
for peptide fibrillization overlaps the putative OLE binding region [294–297]. The interaction of 
oleuropein with Aβ monomers, and the importance of the 17–21 region for it were further confirmed 
by NMR [297,298]; a possible interaction of the secoiridoid also with Aβ oligomers cannot be 
excluded by this technique.  
Most of the research on oleuropein as an aggregation inhibitor was performed on its aglycone 
derivative, which was shown to interfere with both hIAPP and Aβ42 aggregation [299,300]. Structural 
analysis (ThT and Anilinonaphthalene-8-sulfonate binding, CD, Atomic Force Microscopy, TEM) 
showed that OLE does not suppress the final growth of mature amyloid fibrils; rather, it triggers 
peptide precipitation into amorphous aggregates devoid of toxicity, avoiding the formation of toxic 
oligomers. This amorphous precipitate eventually evolves into non-harmful protofibrils, leading to the 
Int. J. Mol. Sci. 2013, 14 12431 
 
ranking of OLE as a Class I inhibitor. For what hIAPP aggregation is concerned, the amorphous 
aggregates that originate during the first phases of incubation in the presence of OLE were shown to be 
unable to interact with, and to damage, the cell membrane [299]. Aβ fibrils can also be remodeled by 
this secoiridoid without release of toxic fragments [300].  
Finally, recent data indicate that OLE can be protective against amyloid aggregation and aggregate 
toxicity not only to cultured cells, but also in vivo. In fact, its administration to a C. elegans strain 
expressing Aβ42 resulted in significant reduction of plaque deposition and toxic oligomer formation 
and improvement of worm performance upon reduction of the extent of paralysis and increase of 
survival [301]. Finally, we recently showed that dietary supplementation of OLE strongly improved 
the cognitive performance of the TgCRND8 mouse model of AD; mice showed remarkably reduced 
plaque deposits, microglia migration to the plaques for phagocytosis, a reduction of the astrocyte 
reaction and an astonishingly intense autophagic reaction. Data obtained with cultured cells confirmed 
that OLE is able to induce autophagy, possibly by acting on the mTOR pathway [302]. OLE protection 
did not merely result from its power as an antioxidant, neither in cells nor in worms [299,303], and was 
more evident when the compound was administered at the beginning of the aggregation process. 
OLE was more effective than oleuropein and hydroxytyrosol (that, anyway, were also active) as an 
inhibitor of Tau fibrillization, with an IC50 of 1.4 μM, as ascertained by both DLS and ThS 
fluorescence assay [304]. While OLE and oleuropein led to a scarce deposition of fibrillar material in 
the form of short rods, hydroxytyrosol induced the growth of fibrils that were less dense, but similar to 
those grown in the absence of any inhibitor. Oleuropein was also shown to modify APP processing, 
increasing the formation of the non-amyloidogenic and neuroprotective sAPPα fragment and to decrease 
Aβ oligomers in HEK695 cell supernatants by increasing matrix metalloproteinase-9 (MMP-9) 
secretion [305].  
Oleocanthal is the dialdehydic form of (−)-deacetoxy-ligstroside aglycone (Figure 6). 
Figure 6. Oleocanthal structure. 
 
It was shown to bind to monomeric or oligomeric Aβ42, inducing the growth of higher molecular 
weight aggregates that were more immunoreactive and less toxic to hippocampal neurons than  
their original counterparts; furthermore, maintaining neurons in oleocanthal for even a short period 
before exposure to toxic oligomers resulted in an effective reduction of their binding to the cell 
membrane [305]. In the same year, oleocanthal was shown to inhibit Tau fibrillization by ThT, EM, 
SPR and MALDI-TOF MS [306]. Most likely, such an inhibition involved chemical crosslinking of 
Tau by reaction of the oleocanthal dialdehydic group with lysine residues, thus arresting the conversion of 
Tau from random coil to β-sheet and promoting an increase of α-helical structure [307]. As already 
observed for Aβ, also in this case, oleocanthal determined the conversion of monomers and oligomers 
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to high molecular weight aggregates, suggesting that crosslinking may be the typical mechanism of 
action of this phenol. Actually, a structure-activity relationship study using several oleocanthal 
analogues clearly indicated that the two aldehydic groups of oleocanthal are essential to prevent Tau 
fibrillogenesis. Interestingly, oleocanthal reveals a certain degree of substrate specificity, showing a 
low reactivity toward free nucleophilic amino acids, such as lysine and arginine, and no binding to 
several other proteins. Studies with transgenic mice recently revealed that this phenol enhances  
β-amyloid clearance from the brain by upregulating Aβ transport proteins at the BBB and Aβ 
degrading enzymes [308].  
A comparison of the very similar chemical structures of OLE and oleocanthal reveals that the main 
difference between them is the presence, in the former, of a methoxycarbonyl group, which dramatically 
increases the acidity of the hydrogen on the adjacent carbon, leading to intramolecular rearrangements 
eventually culminating in the conversion to the dihydropyran form, the main isomer of OLE in 
solution. As a direct consequence, OLE has only one aldehyde function and, so, cannot work as a 
chemical crosslinker, as is the case for oleocanthal [303]. In rat and humans, orally administered olive 
oil phenols, including OLE, its glycoside and/or one of its derivatives arising from tissue metabolism 
are intestinally absorbed, skipping degradation by microorganisms in the colon, cross the blood-brain 
barrier and are found inside brain parenchyma [309,310].  
5.6. Other Phenols 
Among the other natural phenols that have attracted the researchers’ attention, the stilbene, 
nordihydroguaiaretic acid (NDGA), a potent anti-oxidant found in the long-lived creosote bush, and 
the phenolic acid rosmarinic acid (Figure 7), present in may culinary herbs, such as rosemary, oregano, 
sage, thyme and peppermint, were the most investigated, but the results concerning their efficacy were 
not always clear.  
Figure 7. Nordihydroguaiaretic acid (NDGA) and rosmarinic acid structures. 
 
For example, NDGA was first shown to depolymerize preformed Aβ fibrils without release of toxic 
species [311]. This result was subsequently questioned, and it was suggested that, while not 
disaggregating Aβ fibrils or altering protofibril elongation, NDGA would inhibit protofibril-protofibril 
association, possibly by binding along their lateral surface, thus reducing cytotoxicity [312]. Later on, 
a study on the Tg2576 mice model of AD showed that both NDGA and rosmarinic acid reduced Aβ 
plaque burden, but while the latter inhibited the aggregation pathway from Aβ monomers to A11-positive 
oligomers and from these to Aβ fibrils, NDGA mainly inhibited the pathway from A11-positive 
oligomers to Aβ fibrils without interfering with the growth of toxic oligomers [189]. This is the 
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contrary of what was previously demonstrated in vitro, where NDGA inhibited Aβ oligomerization, 
but did not affect its fibrillization [55]. Finally, it was recently shown by PICUP detection of oligomers 
and NMR analysis that NDGA (similarly to myricetin, ferulic acid and Cur) binds to specific peptide 
regions of Aβ monomers, while rosmarinic acid interacts only with oligomers, and all of them prevent 
both oligomerization and fibrillization reducing neuronal toxicity. The authors speculated that the 
negative results reported for NDGA in the mice model by Hamaguchi et al. [188] would derive from a 
low specificity of the A11 antibody in recognizing toxic oligomers [270]. NDGA was only slightly 
effective in reducing TTR aggregation [186], so its efficacy is still a matter of debate. 
The array of natural phenols being tested as potential inhibitors of amyloid aggregation becomes 
wider and wider every day and now includes also tannic acid [207,313] and the product of tannin 
hydrolysis ellagic acid [314]; several flavones, like apigenin [315,316], baicalein [315,317,318], 
kaempferol [260,261,263,264,271,319], morin [265,320,321], fisetin [259,260,321], rutin (the 
glycoside of quercetin with the disaccharide rutinose) [322,323] and luteolin [260,324]; rottlerin, 
already known as a PKC-δ inhibitor [325,326]; the anthocyanidin malvidin, the main responsible for 
the red color of wine [327]; the stilbenes piceatannol [328] and the resveratrol-derived dimer ε-viniferin 
glucoside [329]; and, finally, ferulic acid (related to trans-cinnamic acid) [189,263,264,330–332].  
6. Conclusions  
The last 15 years have seen a huge rise of the interest in degenerative diseases with protein deposits, 
of which amyloid diseases are by far the most important. In particular, the increasing rise of aged 
people in modern countries has stressed what is considered the major risk factor of the sporadic forms 
of these diseases: aging. Presently, AD, PD and type 2 diabetes pose terrific socio-sanitary problems to 
an increasing number of families in the US, Europe, Australia and Japan, together with an 
unsustainable burden to the national health services. The problem is made even worst by the general 
consensus that the occurrence of these pathologies will further increase in the near future. This is why 
increasing efforts are being made to elucidate the molecular basis of protein aggregation into amyloid 
assemblies, both in vitro and in tissue, and the effects of these assemblies on living systems, from the 
simplest ones (cultured cells) to animal models of these pathologies and, eventually, to humans. 
In spite of the steps forward to a better understanding of the molecular pathogenesis of amyloid 
diseases performed in recent years, much must still be learned and a deeper knowledge appears 
mandatory to develop therapeutic approaches to these diseases, which are presently lacking. However, 
in parallel with many studies on the molecular basis of protein aggregation and aggregate toxicity, 
many efforts have been spent, and are presently under way, to test and to explain, when present, the 
anti-aggregation and cell protective power of a wide panel of natural or synthetic chemicals, some of 
which are already in use as antibiotics or other drugs. The problem with most of these chemicals is that 
they are not suitable for long-term administration in possibly high doses; other problems are associated 
with the way of administration and their possible side-effects, as it was found for immunological 
therapy. Nevertheless, research is going on, and it is expected that some of these chemicals, 
particularly the antibodies raised by passive or active immunotherapy, will become effective 
therapeutic tools without significant side-effects. 
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The very complex picture of the biological determinants of protein aggregation, the interplay 
between the structural features underlying the cytotoxicity of specific amyloid assemblies and of cell 
vulnerability to their toxicity, the specific cell/tissue functionally aberrant responses to the presence of 
amyloid deposits, the biological tools protecting cells against amyloid toxicity, and many others, make 
it very difficult to find specific drugs with effective therapeutic potential. These considerations are 
further stressed by the fact that in most amyloid diseases, the appearance of early symptoms signals a 
condition where cell/tissue damage is too severe to be reversed. However, an alternative possibility is 
provided by molecules whose continued administration is able to counteract any of these aberrant 
situations, so as to reduce the extent of cell/tissue insult or to delay it significantly. It is evident that 
delaying the appearance of the symptoms of age-associated conditions, such as AD or PD, would 
greatly reduce the prevalence of the latter in the aged population. 
Many natural phenolic substances occur in a vast array of vegetables, herbs and fruits, some of 
which are important components of the diet of specific populations: this is the case for East Asian 
spices and herbs enriched in Cur and EGCG or the MD in a number of countries lining the 
Mediterranean sea, characterized by the use of EVOO and red wine, whose phenolic substances 
(resveratrol, oleuropein aglycone, oleocanthal) are continuously taken up in variable, yet significant, 
amounts with the diet. Increasing molecular, biochemical, biological and clinical information support 
the notion that at least some of these substances possess beneficial properties that are associated not 
only with a reduction of the aggregation power of specific peptides/proteins associated with amyloid 
diseases, but also with the ability to stimulate cell defenses against the insult given by these 
aggregates, thus providing a convincing explanation of the recognized protection of these diets against 
a number of pathological conditions, including aging and age-associated pathologies, such as PD and 
dementia. These substances can be seen as nutraceuticals rather than drugs and can be administered in 
larger amounts than specific drugs; moreover, the possibility to fortify diet components, such as wine 
and olive oil, with these substances could be a way to take them up for long time periods, replenishing 
possible deposits in the organism (most of them are hydrophobic molecules that, similarly to lipid 
vitamins, could be stored in the adipose tissue), possibly providing continuous protection and a way to 
delay aging, dementia and other neurodegenerative diseases. More information is needed for the 
possible use of any of these compounds in humans, and convincing clinical trials are still to be carried 
out. Nevertheless, these substances undoubtedly represent molecules with high potential as effective 
therapeutic/prophylactic tools to treat amyloid diseases. 
These natural compounds can also be regarded as tools to investigate the amyloid aggregation 
pathway and as molecular scaffolds for the development of more active and biologically available 
drugs. In this respect, a major problem that emerges from this review is the absence of a rigorously 
defined methodological and technical framework to which the researchers, willing to investigate this 
peculiar class of amyloid inhibitors, should adapt. As we have outlined, some widely used assays 
suffer from an interference of phenolics, which is not always adequately taken into account; on top of 
this, a clear definition of what is intended for ―oligomers‖, ―pre-fibrillar aggregates‖ and ―fibrils‖ is 
still lacking. The need to standardize the in vitro and in vivo assay conditions is compelling in order to 
rigorously determine the efficacy, specificity and potency of these promising inhibitors.  
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